{"id":654593,"date":"2023-06-07T13:00:02","date_gmt":"2023-06-07T13:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=654593"},"modified":"2023-06-07T13:00:02","modified_gmt":"2023-06-07T13:00:02","slug":"gene-therapy-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-juno-pharma-candle-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/gene-therapy-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-juno-pharma-candle-pharma_654593.html","title":{"rendered":"Gene Therapy  Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies &#8211; Juno Pharma, Candle Pharma"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Gene Therapy  Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies - Juno Pharma, Candle Pharma\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Gene Therapy  Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies - Juno Pharma, Candle Pharma\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(Nevada, Las Vegas) United States, DelveInsight\u2019s \u201cGene Therapy Competitive landscape, 2023,\u201d report provides comprehensive insights about 250+ companies and 300+ drugs in the CAR T &#8211; Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">(Nevada, Las Vegas) United States, DelveInsight&rsquo;s &ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Gene Therapy Competitive landscape, 2023<\/a>&rdquo; report provides comprehensive insights about 250+ companies and 300+ drugs in the CAR T &#8211; Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Takeaways from the Gene Therapy TherapyPipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leading Gene&nbsp; Therapy companies developing novel drug candidates are Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, Istari Oncology, Immvira Pharma, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, Tasly Pharmaceuticals, and many others<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Promising Gene Therapy pipeline therapies in various stages of development include BREYANZI, Valoctocogene Roxaparvovec, TILT-123, NG-347<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Gene Therapy Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Gene Therapy is a technique that uses a gene(s) to treat, prevent or cure a disease or medical disorder. Often, Gene Therapy works by adding new copies of a gene that is broken, or by replacing a defective or missing gene in a patient&rsquo;s cells with a healthy version of that gene. Both inherited genetic diseases (e.g., hemophilia and sickle cell disease) and acquired disorders (e.g., leukemia) have been treated with&nbsp; Gene Therapy. Gene Therapy is the use of genetic material to treat or prevent disease. The genetic material that is delivered, DNA or RNA, has instructions to change how a protein&mdash;or group of proteins&mdash;is produced by the cell. For some diseases, this means making changes to account for too much, not enough, or incorrect essential proteins being produced within cells. This new genetic material, such as a working gene, is delivered into the cell using a vector. A vector is like a package used to deliver a specific message.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/bc37b6b9d187831299113fb1d0d8bce2.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Discover more about the emerging Gene Therapy drugs @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">GeneTherapy&nbsp; Treatment Drugs<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;Gene <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Therapy Pipeline Therapies and Key Companies<\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Juno Therapeutics: BREYANZI<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BioMarin Pharmaceutical:&nbsp; Valoctocogene Roxaparvovec<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Candel Therapeutics: CAN-2409<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;CRISPR Therapeutics: CTX001<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Scope of the Gene&nbsp; Therapy&nbsp; Pipeline Report&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage:&nbsp;Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Gene Therapy Companies: Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, Istari Oncology, Immvira Pharma, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, Tasly Pharmaceuticals and many others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Gene Therapy Pipeline Therapies: BREYANZI, Valoctocogene Roxaparvovec, CAN-2409,&nbsp; CTX001, and many others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Find out more about the Gene Therapy treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">CAR T &#8211; Cell Therapy&nbsp; Clinical Trials<\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Table of Contents<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1 Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3 Gene Therapy: Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3.1 Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3.2Mechanism of Action<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3.3Application<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3.4Limitation<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3.5Approved Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4 GeneTherapy-Analytical Perspective: In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4.1Gene Therapy Collaboration Analysis by Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Competitive Landscape<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4.2Comparative Assessment of Companies (by therapy, development stage, and technology)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5.1Assessment by Product Type<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5.2Assessment by Stage and Product Type<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5.3Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5.4Assessment by Stage and Route of Administration<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5.5Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5.6Assessment by Stage and Molecule Type<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6 Gene Therapy: Company and Product Profiles (Marketed Therapies)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">JW Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6.1Company Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Relmacabtagene autoleucel<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6.2Product Description<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6.3Research and Development Activities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6.4Product Developmental Activities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7 GeneTherapy: Company and Product Profiles (Pipeline Therapies)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7.1Late Stage Products (Registered)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7.2Comparative Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">CARsgen<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7.3Company Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Zevorcabtagene autoleucel<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7.4Product Description<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7.5Research and Development Activities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7.6Product Developmental Activities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8.1Comparative Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Cartesian Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8.2Company Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Descartes 011<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8.3Product Description<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8.4Research and Development Activities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8.5Product Developmental Activities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9.1Comparative Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Autolus Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9.2Company Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">AUTO-8<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9.3Product Description<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9.4Research and Development Activities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9.5Product Developmental Activities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10Preclinical and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10.1Comparative Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Sana Biotechnology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10.2Company Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">SG299<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10.3Product Description<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Research and Development Activities<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">10.4Product Developmental Activities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10.5Products<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Comparative Analysis<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Gene Therapy &#8211; Unmet needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Gene Therapy&ndash; Market drivers and barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Appendix<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=gene-therapy-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-juno-pharma-candle-pharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=gene-therapy-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-juno-pharma-candle-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP (Nevada, Las Vegas) United States, DelveInsight\u2019s \u201cGene Therapy Competitive landscape, 2023,\u201d report provides comprehensive insights about 250+ companies and 300+ drugs in the CAR T &#8211; Cell Therapy Competitive landscape. It covers the therapeutics assessment by &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/gene-therapy-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-juno-pharma-candle-pharma_654593.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-654593","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/654593","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=654593"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/654593\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=654593"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=654593"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=654593"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}